Calcium dysregulation in diabetic cardiomyopathy & heart failure with preserved ejection fraction
-
By
-
Anza Ali
-
Vineet M. Sharma
-
Yuriana Aguilar-Sanchez
-
June 23, 2026
-
Clinical Scorecard: Calcium Imbalance in Diabetic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction
At a Glance
| Category | Detail |
|---|
| Condition | Diabetic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction |
| Key Mechanisms | Impairment of calcium-handling cardiac proteins such as SERCA2a and RyR2 contributes to cardiac dysfunction. |
| Target Population | Patients with type 2 diabetes (T2D) and heart failure, particularly HFpEF. |
| Care Setting | Clinical research and trials focusing on diabetes-induced cardiomyopathy. |
Key Highlights
- Diabetes is a major risk factor for cardiovascular disease and heart failure.
- DbCM is characterized by cardiac dysfunction without significant coronary artery disease.
- Calcium mishandling plays a critical role in the progression of DbCM.
- Current therapies do not reverse disease progression in DbCM or HFpEF.
- AAV-mediated gene therapies show promise for treating diabetes-induced cardiomyopathy.
Guideline-Based Recommendations
Diagnosis
- Diabetic cardiomyopathy should be diagnosed in the absence of significant coronary artery disease, hypertension, or valvular heart disease.
Management
- Focus on molecular pathways affected in DbCM and HFpEF.
Monitoring & Follow-up
- Monitor calcium-handling proteins and cardiac function in patients with T2D.
Risks
- Increased risk of heart failure due to diabetes-induced cardiac impairment.
Patient & Prescribing Data
Patients with type 2 diabetes and heart failure.
Current treatments target symptoms but do not reverse progression; gene therapies are under investigation.
Clinical Best Practices
- Assess cardiac function regularly in patients with diabetes.
- Investigate the role of calcium-handling proteins in cardiac health.
- Consider participation in clinical trials for emerging therapies.
Related Resources & Content
